Skip to main content

Prosecution history estoppel.

Prosecution history estoppel is a legal doctrine that applies to patent law. It is a principle that limits the scope of patent claims based on the statements made by the patent applicant or the patent office during the prosecution (examination) of the patent application. The doctrine is designed to prevent a patent applicant from making inconsistent or contradictory arguments to the patent office to secure broader claim scope during prosecution and then asserting a different, narrower interpretation of the claims in later infringement litigation.

When a patent application is being examined by a patent office, the applicant and the examiner engage in a back-and-forth process called prosecution, where the applicant amends and argues the scope of the patent claims. The applicant may make arguments to distinguish their invention from prior art references or to overcome rejections based on prior art.

Prosecution history estoppel comes into play if, during the prosecution, the applicant voluntarily or involuntarily makes statements that:

1. Amend the claims: If the applicant amends the claims to make them more specific or to distinguish them from prior art, the amended language is presumed to limit the scope of the claims. This means the patent owner may be prevented from arguing that the claims cover subject matter that was surrendered during prosecution.

2. Surrender scope: If the applicant makes arguments to the patent office to overcome prior art rejections, those arguments may be viewed as a disclaimer or surrender of certain claim scope. In such cases, the patent owner may be estopped from later asserting that the surrendered subject matter is within the scope of the claims.

The doctrine of prosecution history estoppel aims to ensure that the patent owner cannot expand the scope of their claims beyond what was allowed or confirmed during the prosecution process. It promotes certainty and fairness in patent litigation by preventing a patent owner from adopting inconsistent positions on claim interpretation.

It's essential for patent applicants to carefully consider their arguments and claim amendments during prosecution, as these can have significant implications for claim scope and enforceability in later litigation. Additionally, parties involved in patent disputes should thoroughly analyze the prosecution history to understand the potential impact of prosecution history estoppel on claim interpretation and validity.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcur...

Corona virus (Covid-19)

The only way one can combat with Covid-19 is by building one’s immunity & staying healthy by proper hygiene Best medicines for immunity development could be multivitamin pills with zinc,and best foods could be #freshfruits #vegetables. #Mangoes #lemon #oranges are could be the best.

Biogen to seek approval for high-dose version of Spinal Muscular Atrophy stalwart Spinraza (Nusinersen) after trial win

Biogen, which was first to score an endorsement in Spinal Muscular Atrophy (SMA) in 2016, is endeavoring to address it with a higher portion variant of Spinraza #(Nusinersen). On Wednesday, the organization uncovered that a part of its stage 2/3 Commit concentrate on met its essential endpoint, as a higher portion of Spinraza worked on the engine capability of treatment-innocent newborn children with SMA. The review contrasted the high-portion routine with a coordinated, untreated hoax control bunch from the stage 3 Charm study, which empowered Spinraza's unique endorsement. In the Commit preliminary accomplice, 75 patients were randomized 2:1 to get the higher-portion routine or the FDA-endorsed dose of 12 mg, which incorporates four beginning medicines, trailed by support dosages like clockwork. While the high-portion form of Spinraza met the preliminary's endpoint contrasted with joke, the outcomes too "moved in favor" of the investigational routine contrasted with...